



Pixium Vision's 2018 financial calendar

Paris, December 28, 2017 – 6.00 PM CET - Pixium Vision (FR0011950641 - PIX), a company developing innovative bionic vision systems to enable patients who have lost their sight to lead more independent lives, announces its 2018 financial calendar*:

- February 8, 2018 – Full year 2017 financial results
- April 26, 2018 – Sales for the first quarter of 2018
- June 27, 2018 – Annual General Shareholders' Meeting
- July 26, 2018 – Half year 2018 financial results
- October 25, 2018 – Sales for the first nine month of 2018

** This financial calendar is for indicative purposes only. Pixium Vision may change the above dates if deemed necessary.*

Contacts

Pixium Vision

Didier Laurens, CFO

investors@pixium-vision.com

+33 1 76 21 47 68



@PixiumVision

Media Relations

France: Newcap Media

Annie-Florence Loyer - afloyer@newcap.fr

+33 1 44 71 00 12 / +33 6 88 20 35 59

Léa Jacquin - ljacquin@newcap.fr

+33 1 44 71 94 94

Media Relations

International: Image Box PR

Neil Hunter

neil@imageboxpr.co.uk

Tel +44 (0)20 8943 4685

ABOUT PIXIUM VISION

Pixium Vision's mission is to create a world of bionic vision for those who have lost their sight, enabling them to regain partial visual perception and greater autonomy. Pixium Vision's bionic vision systems are associated with a surgical intervention as well as a rehabilitation period. Following the CE mark for its first bionic retinal implant systems, IRIS®II, Pixium Vision is now conducting a clinical study in Human with PRIMA, its next generation sub-retinal miniaturized photovoltaic wireless implant system, for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners spanning across the prestigious Vision research institutions including the Institut de la Vision in Paris, the Hansen Experimental Physics Laboratory at Stanford University, Moorfields Eye Hospital in London, and Institute of Ocular Microsurgery (IMO) in Barcelona. The company is EN ISO 13485 certified. Pixium Vision is qualified "Entreprise Innovante" par Bpifrance

For more information, please visit:  www.pixium-vision.com;

And follow us on:  @PixiumVision;  www.facebook.com/pixiumvision

Linked  www.linkedin.com/company/pixium-vision



Pixium Vision is listed on Euronext Paris (Compartment C). Pixium Vision shares are eligible for the French tax incentivized PEA-PME and FCPI investment vehicles.

Pixium Vision is included in the Euronext CAC All Shares index

Euronext ticker: PIX - ISIN: FR0011950641 – Reuters: PIX.PA – Bloomberg: PIX:FP

Disclaimer:

This press release may expressly or implicitly contain forward-looking statements relating to Pixium Vision and its activity. Such statements are related to known or unknown risks, uncertainties and other factors that could lead actual results, financial conditions, performance or achievements to differ materially from Vision Pixium results, financial conditions, performance or achievements expressed or implied by such forward looking statements.

Pixium Vision provides this press release as of the aforementioned date and does not commit to update forward looking statements contained herein, whether as a result of new information, future events or otherwise.

For a description of risks and uncertainties which could lead to discrepancies between actual results, financial condition, performance or achievements and those contained in the forward-looking statements, please refer to Chapter 4 "Risk Factors" of the company's Registration Document filed with the AMF under number R16-033 on April 28, 2016 which can be found on the websites of the AMF - AMF (www.amf-france.org) and of Pixium Vision (www.pixium-vision.com).

IRIS® is a trademark of Pixium-Vision SA